Skip to main content
. 2020 Sep;12(9):4643–4650. doi: 10.21037/jtd-19-3790

Figure S3.

Figure S3

Median overall survival (mOS) for the 43 metastatic patients with single uncommon EGFR mutation, considering the EGFR uncommon mutation. p.Glu709X (n=5): mOS =18.0 months [16.8−NA]; p.Gly719X) (n=20): mOS =18.0 months [10.8-NA]; p.Ser768Ile (n=6): mOS=32.4 months [1.2-NA]; p.Ala767_Val769dup (n=14): mOS= 16.8 months [7.2−NA]; p.Leu861Gln (n=20): mOS =9 months [4.8−NA].